Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
Metadata only so far. Questions are answered only with quotes from this document. Source: ClinicalTrials.gov, retrieved 2026-11-04.
Stopped earlyWhy stopped, per the registry: “A business decision to place screening/enrollment on hold. Study redesign/amendment pending additional Ampligen-related data from an ongoing Phase I-II open label study (NCT05927142)”
Record metadata
- Phase
- Phase 2
- Status
- Suspended
- Start
- 2027-08
- End
- 2031-03
- Enrollment
- 90
- Sites
- 3
- Sponsor class
- INDUSTRY
Not in the data yet: a trial card. A one-glance card (population, design, endpoints, result, each tied to a quote) is not built yet. The fields above are registry or bibliographic metadata, not quotes.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you get that instead of a guess.
Source text
No passages are loaded for this document yet.